http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2018133271-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_13d198ea5c8a5f4c2f05ff8c4bf2aba3 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2200-30 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23V2002-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A23L33-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-716 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K36-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A23L33-10 |
| filingDate | 2016-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d263202ffe67a621bda67a716c1ab882 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_179d1d887c2c719334e1d63051205812 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b8f0e1c413f3f1581b5993cefb83d7d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1fc30a8bc85085096fa376f16144717 |
| publicationDate | 2018-05-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2018133271-A1 |
| titleOfInvention | Suppressive agent for rheumatoid arthritis, prophylactic agent for rheumatoid arthritis, therapeutic agent for rheumatoid arthritis, and food for suppressing rheumatoid arthritis |
| abstract | Provided are an inhibitor, a prophylactic, and a therapeutic agent for rheumatoid arthritis that have no side effects and that can correct immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent for rheumatoid arthritis contain a Euglena -derived material as an active ingredient. The inhibitor, the prophylactic and the agent are used as an antirheumatic drug for controlling the activity of rheumatoid arthritis by alleviating immune abnormality associated with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are also used for a living individual who has not been definitively diagnosed with rheumatoid arthritis. The inhibitor, the prophylactic, and the agent are continuously administered to the living individual from any point before definitive diagnosis of rheumatoid arthritis to any point after the definitive diagnosis. The Euglena -derived material is at least one material selected from the group including Euglena algae, paramylon derived from the Euglena , water-soluble amorphous paramylon prepared by treating the paramylon with alkali and neutralizing the treated paramylon, and emulsion paramylon prepared by ejecting a solution of the paramylon from a narrow bore nozzle at a very high pressure to cause the solution to collide with a collision surface. |
| priorityDate | 2015-04-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.